TL;DR
- •Akathisia is a movement disorder consisting of intense inner restlessness plus a compulsion to move, most often pacing, rocking, or an inability to keep the legs still.
- •It is frequently misdiagnosed as worsening anxiety or agitated depression, and that error is consequential because the usual response, increasing the dose, makes akathisia worse.
- •Antidepressants can cause it. Pharmacovigilance analysis of the global safety database confirms movement disorders including akathisia as a recognized antidepressant adverse effect, not solely an antipsychotic one.
- •Aripiprazole (Abilify) carries a well-documented akathisia risk, and it is commonly added to antidepressants as augmentation for treatment-resistant depression, making this a frequent scenario in psychiatric care.
- •Onset is typically within days to a few weeks of starting or increasing the dose, which distinguishes it from baseline anxiety.
- •Akathisia is associated with significant distress and has been linked in the literature to suicidal ideation, which is why it warrants prompt clinical attention rather than watchful waiting.
- •It is treatable. Dose reduction or withdrawal of the causative agent is primary, and network meta-analysis has evaluated the comparative efficacy of pharmacological treatments.
Medications most associated with this
What this is
Patients describe akathisia as one of the most distressing experiences they have had on psychiatric medication, and they often struggle to find words for it. Typical descriptions include needing to jump out of their own skin, a motor that will not switch off, and an unbearable compulsion to move that brings no relief when they do. Outward signs include pacing, rocking while seated, shifting weight from foot to foot, crossing and uncrossing the legs, and an inability to remain seated through a meal or a meeting. The defining feature is the combination of an internal sense of restlessness with an external compulsion to move. Critically, patients often report that it does not feel like their usual anxiety, and that distinction, when a patient offers it, deserves to be taken seriously.
Why it happens
Akathisia is understood as a drug-induced movement disorder arising from disruption of dopaminergic signaling in motor and limbic pathways, with serotonergic modulation of dopamine release implicated in the antidepressant-associated form. Serotonergic agents can suppress dopamine transmission in nigrostriatal pathways, which provides a mechanistic route by which SSRIs and SNRIs produce a syndrome once considered specific to antipsychotics. Analysis of the World Health Organization global pharmacovigilance database has documented antidepressants and movement disorders including akathisia, establishing this as a recognized class effect rather than an anomaly. For aripiprazole, the mechanism relates to partial dopamine D2 agonism, and meta-analysis of akathisia incidence has quantified the risk relative to comparator agents. Because aripiprazole is widely used to augment antidepressants in treatment-resistant depression, patients on combination regimens face contributions from both agents.
Typical timeline
Onset is characteristically early, within days to a few weeks of starting the drug or increasing the dose, and this temporal relationship is the most valuable diagnostic information available. Acute akathisia usually improves within days to weeks once the causative agent is reduced or stopped, although the timeline varies with the drug half-life. A minority of patients experience a more persistent form that outlasts discontinuation and requires specific management. The most dangerous window is the early period when the syndrome is most likely to be misread as worsening anxiety or agitation, prompting a dose increase that intensifies the akathisia and deepens the patient distress. Any new restlessness appearing shortly after a medication change should be evaluated with akathisia explicitly in mind.
Management options
Discuss with your prescriber before adjusting any medication. These are options to bring up in conversation.
Contact your prescriber promptly, and say the word akathisia
This is the step that matters most, and it is time-sensitive rather than routine. Naming akathisia specifically helps, because the syndrome is commonly recorded as anxiety or agitation, and that mislabeling leads to a dose increase that makes it worse. Describe both the internal restlessness and the compulsion to move, and state when it began relative to your last dose change.
Do not increase the dose to treat the restlessness
The instinct to treat agitation with more medication is exactly backwards here. If the causative agent is the antidepressant or aripiprazole, escalation intensifies the syndrome. Equally, do not stop abruptly on your own, since that carries its own risks. The change needs to be a prescriber decision.
Reduce or withdraw the causative agent
This is the primary treatment. Dose reduction is usually the first move, and where akathisia is severe, switching agents entirely may be necessary. In combination regimens, the augmenting antipsychotic is frequently the more likely culprit and the first candidate for adjustment.
Pharmacological treatment where adjustment is insufficient
Where the causative drug cannot be reduced quickly enough or symptoms are severe, specific pharmacological options exist. A network meta-analysis has compared their relative efficacy for antipsychotic-induced akathisia, giving prescribers an evidence base to choose from. This is a prescriber decision, not a self-management step.
Seek urgent help if distress becomes severe
Akathisia has been associated in the literature with suicidal ideation, and the subjective distress can escalate quickly. If the restlessness becomes unbearable or you begin having thoughts of harming yourself, treat it as urgent and contact your prescriber, an urgent care service, or a crisis line immediately.
Where ketamine fits
Akathisia most often arises in exactly the population where treatment options already feel constrained: patients with treatment-resistant depression who have moved on to antipsychotic augmentation, most commonly aripiprazole, after antidepressant monotherapy failed. When that augmentation produces intolerable akathisia, the patient is left needing an alternative path. Ketamine works through NMDA receptor antagonism and downstream glutamatergic signaling rather than dopamine receptor blockade or partial agonism, so it does not carry the mechanism that produces akathisia. For a patient whose depression required augmentation and who cannot tolerate the augmenting agent, this is a clinically relevant alternative to discuss. Acute akathisia should be addressed first as its own urgent problem. Ketamine is a consideration for the underlying depression afterward, not a treatment for the akathisia itself.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL, NJ & CA
Frequently asked
How do I know if this is akathisia or just anxiety?
The most useful distinctions are the compulsion to move and the timing. Anxiety is primarily a mental and emotional state, whereas akathisia pairs inner restlessness with a physical drive to move that brings no relief. Akathisia also typically begins within days to weeks of a medication start or dose increase. If your restlessness feels qualitatively different from your usual anxiety, say so explicitly to your prescriber, because that observation carries real diagnostic weight.
Why is it dangerous to treat this as anxiety?
Because the standard response to worsening anxiety is often a dose increase, and if the medication is causing the akathisia, that makes it worse. This misattribution loop is well recognized and is the main reason to name akathisia specifically when you describe your symptoms.
Which medication is most likely responsible if I take several?
In combination regimens for treatment-resistant depression, the augmenting antipsychotic is frequently the more likely contributor, and aripiprazole in particular has a well-documented akathisia risk. That said, SSRIs and SNRIs can cause it on their own. The timing of your symptoms relative to each medication change is what lets your prescriber identify the culprit.
Will it go away?
In most cases, yes. Acute akathisia typically resolves within days to weeks once the causative drug is reduced or stopped, with the exact timeline depending on the drug half-life. A minority of patients develop a more persistent form requiring specific treatment, which is another reason to address it early rather than waiting.
Should I stop the medication myself?
No. Stopping antidepressants or antipsychotics abruptly carries real risks including discontinuation syndrome and relapse. Contact your prescriber promptly and describe what you are experiencing. If the distress is severe or you are having thoughts of harming yourself, treat it as an emergency and seek help immediately rather than waiting for a scheduled appointment.
Related reading
Don’t stop your medication on your own
Even mild side effects deserve a clinical conversation. Stopping or adjusting antidepressants without coordination with your prescriber can cause discontinuation syndrome, depression breakthrough, or both. Bring these options to your next appointment.
References
- Revet A et al. 2020, BMC Psychiatry. Postmarketing analysis of the WHO global pharmacovigilance database documenting antidepressants and movement disorders including akathisia. PMID 32546134
- Thomas JE et al. 2015, Current Neuropharmacology. Meta-analysis of akathisia incidence with aripiprazole, asenapine, and lurasidone. PMID 26467415
- Gerolymos C et al. 2024, JAMA Network Open. Systematic review and network meta-analysis of drug efficacy in the treatment of antipsychotic-induced akathisia. PMID 38451521
- Salem H et al. 2017, Current Neuropharmacology. Review of antipsychotic-induced akathisia covering mechanism, clinical recognition, and management challenges. PMID 27928948